SynCore Biotechnology Co (杏國新藥) has begun the race to introduce SB05PC, its new pancreatic cancer drug, to the Chinese market as a first-line treatment.
The company has begun enrolling patients in a global phase III clinical trial, that is to take place in seven countries, including the US.
The drug would be used as a second-line treatment in combination with gemcitabine for those who have exhausted other commonly prescribed first-line chemotherapy treatments such as FOLFIRINOX.
SB05PC would be competing against PharmaEngine Inc’s (智擎) onivyde, which has been approved and covered by the National Health Insurance (NHI) program since August.
“Gaining marketing approval from the US Food and Drug Administration would greatly improve SynCore’s odds of succeeding in the Chinese market, where the availability of first-line options is lacking, in particular FOLFIRINOX,” SynCore general manager Su Muh-hwan (蘇慕寰) said.
The company would be required conduct a separate clinical trial if it wants to introduce SB05PC as a first-line treatment and tap into the immense Chinese market for pancreatic treatments, which has yet to be dominated by an established product, Su said.
The company has enrolled its second patient in Taiwan for the phase III global trial and should be able to enroll the required 218 patients before the end of next year, Su said.
“Once site visits are completed in the the US and China, the pace of patient enrollments should pick up dramatically,” Su said, adding that health authorities in France, Hungary, South Korea and Russia have approved SB05PC’s phase III global trial.
The company has also applied for FOLFIRINOX to be covered by the NHI, Su said.
“Based on the results of the phase II trial, we are confident that phase III will meet its primary efficacy endpoint and produce a 40 percent improvement in terms of overall survival among enrolled patients,” said Hsieh Ruey-kuen (謝瑞坤), a physician and a director at the Taiwan Cooperative Oncology Group who worked with SynCore in designing SB05PC’s clinical trial parameters.
Phase III is basically the same study as phase II, only with more patients enrolled to meet regulatory requirements, Hsieh said, adding that SB05PC’s toxicity profile is relatively lower compared with other second-line drugs.
Intel Corp chief executive officer Lip-Bu Tan (陳立武) is expected to meet with Taiwanese suppliers next month in conjunction with the opening of the Computex Taipei trade show, supply chain sources said on Monday. The visit, the first for Tan to Taiwan since assuming his new post last month, would be aimed at enhancing Intel’s ties with suppliers in Taiwan as he attempts to help turn around the struggling US chipmaker, the sources said. Tan is to hold a banquet to celebrate Intel’s 40-year presence in Taiwan before Computex opens on May 20 and invite dozens of Taiwanese suppliers to exchange views
Application-specific integrated circuit designer Faraday Technology Corp (智原) yesterday said that although revenue this quarter would decline 30 percent from last quarter, it retained its full-year forecast of revenue growth of 100 percent. The company attributed the quarterly drop to a slowdown in customers’ production of chips using Faraday’s advanced packaging technology. The company is still confident about its revenue growth this year, given its strong “design-win” — or the projects it won to help customers design their chips, Faraday president Steve Wang (王國雍) told an online earnings conference. “The design-win this year is better than we expected. We believe we will win
Quanta Computer Inc (廣達) chairman Barry Lam (林百里) is expected to share his views about the artificial intelligence (AI) industry’s prospects during his speech at the company’s 37th anniversary ceremony, as AI servers have become a new growth engine for the equipment manufacturing service provider. Lam’s speech is much anticipated, as Quanta has risen as one of the world’s major AI server suppliers. The company reported a 30 percent year-on-year growth in consolidated revenue to NT$1.41 trillion (US$43.35 billion) last year, thanks to fast-growing demand for servers, especially those with AI capabilities. The company told investors in November last year that
Power supply and electronic components maker Delta Electronics Inc (台達電) yesterday said it plans to ship its new 1 megawatt charging systems for electric trucks and buses in the first half of next year at the earliest. The new charging piles, which deliver up to 1 megawatt of charging power, are designed for heavy-duty electric vehicles, and support a maximum current of 1,500 amperes and output of 1,250 volts, Delta said in a news release. “If everything goes smoothly, we could begin shipping those new charging systems as early as in the first half of next year,” a company official said. The new
RSS